Completed |
: A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
: - Fallopian Tube Carcinoma
- Malignant Ovarian Mixed Epithelial Tumor
-
- Biological: Urokinase-Derived Peptide A6
|
Completed |
: Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
: - Brenner Tumor
- Fallopian Tube Cancer
- Ovarian Clear Cell Cys
: 2007-04-25
: - Biological: sargramostim Given
|
Completed |
: Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
: - Brenner Tumor
- Fallopian Tube Cancer
- Ovarian Clear Cell Cys
: 2004-03-08
: - Procedure: adjuvant therapy
- Drug: paclitax
|
Completed |
: Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
: - Fallopian Tube Carcinoma
- Malignant Ovarian Mixed Epithelial Tumor
-
- Drug: Carboplatin Given IV
|
Recruiting |
: Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy
: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Tumor
-
- Other: Laboratory Biomarker Analysis
|
Withdrawn |
: Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
: - Fatigue
- Malignant Ovarian Mixed Epithelial Tumor
- Neuropath
: 2011-12-14
: - Dietary Supplement: Acetyl-L-Carnitine Hydrochloride
|
Active, not recruiting |
: Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy
: - Cognitive Side Effects of Cancer Therapy
- Malignant Ovarian Epithelial Tumor
-
- Procedure: Cognitive Assessment
|
Active, not recruiting |
: Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
: 2010-02-23
: - Drug: Bortezomib Given IP
|
Completed |
: Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
: - Chemotherapeutic Agent Toxicity
- Endometrial Adenocarcinoma
: 2008-12-20
: - Drug: Paclitaxel Given IV or i
|
Completed |
: Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
: - Brenner Tumor
- Fallopian Tube Cancer
- Ovarian Carcinosarcoma
: 2004-06-10
: - Drug: carboplatin Given intrap
|